Quoin Pharmaceuticals Expands QRX009 Platform with Multi-Indication Clinical Roadmap for 2026
Quoin Pharmaceuticals (NASDAQ: QNRX) has outlined a clinical and regulatory roadmap that expands the development path for QRX009, its proprietary topical rapamycin platform. The company is planning to advance QRX009 into up to four rare disease indications by the end of 2026, building out a broader pipeline alongside its lead Netherton Syndrome program.
From Platform to Pipeline: Advancing QRX009 into the Clinic
Quoin is preparing to initiate an investigator-led clinical study in Pachyonychia Congenita (PC), a rare and painful genetic skin disorder with no approved treatments. The study will be led by Professor Edel O’Toole of Queen Mary University of London, a widely recognized clinical authority in PC with prior trial experience in the indication. Initiation is targeted for the third quarter.
Two additional investigator-led studies are planned later this year in Gorlin Syndrome and Tuberous Sclerosis Complex, both rare diseases with significant unmet need and a well-established biological rationale for rapamycin-based therapies. In parallel, Quoin remains on track to submit an Investigational New Drug application to the U.S. FDA for QRX009 in a separate indication in the third quarter.
Expanding Across Rare Dermatology Indications
The update reflects a clear expansion of the QRX009 narrative. What was previously positioned as an early-stage platform is now moving toward clinical evaluation across multiple indications, each in settings characterized by limited competition and high unmet need. Quoin has also established working relationships with patient advocacy organizations active in these indications, including PC Project and the Gorlin Syndrome Alliance.
Positioned Alongside a Late-Stage Anchor Program
The QRX009 update comes as Quoin advances its lead program, QRX003, toward a registrational Phase 3 study in Netherton Syndrome. Following a recent Type C meeting with the FDA, the company received guidance indicating that a single Phase 3 study may be sufficient to support marketing approval. Quoin remains on track to initiate its Phase 3 study and complete patient recruitment in 2026, with topline data from ongoing whole-body studies expected in the second half of the year and a potential NDA filing in 2027.
The addition of QRX009 introduces a second development vector alongside the late-stage QRX003 program, broadening the rare disease pipeline across multiple indications and stages of development.
A Year of Multiple Catalysts Ahead
With investigator-led studies planned across PC, Gorlin Syndrome, and Tuberous Sclerosis Complex, an additional IND submission targeted for the third quarter, and topline Netherton Syndrome data expected in the second half of the year, Quoin’s 2026 calendar carries a notable density of clinical and regulatory milestones. The company has previously disclosed eligibility for expedited review pathways across its core territories, including Fast Track Designation and Orphan Drug Designation in the United States, Orphan Drug Designation in Europe, and confirmation of eligibility for Orphan Drug Designation and Fast Track review in Japan.
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
